Source: Lancet Regional Health-Americas. Unidade: FM
Subjects: ESCLEROSE MÚLTIPLA, ADULTOS, FÁRMACOS, SISTEMA NERVOSO CENTRAL, BRASIL, DIAGNÓSTICO PRECOCE
ABNT
SILVA, Guilherme Diogo et al. Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs. Lancet Regional Health-Americas, v. 49, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/88369. Acesso em: 22 abr. 2026.APA
Silva, G. D., Pipek, L. Z., Oliveira, M. B. de, Apostolos-pereira, S. L., Adoni, T., Lino, A. M. M., et al. (2025). Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs. Lancet Regional Health-Americas, 49. doi:10.1016/j.lana.2025.101171NLM
Silva GD, Pipek LZ, Oliveira MB de, Apostolos-pereira SL, Adoni T, Lino AMM, Callegaro D, Castro LHM. Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs [Internet]. Lancet Regional Health-Americas. 2025 ; 49[citado 2026 abr. 22 ] Available from: https://observatorio.fm.usp.br/handle/OPI/88369Vancouver
Silva GD, Pipek LZ, Oliveira MB de, Apostolos-pereira SL, Adoni T, Lino AMM, Callegaro D, Castro LHM. Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs [Internet]. Lancet Regional Health-Americas. 2025 ; 49[citado 2026 abr. 22 ] Available from: https://observatorio.fm.usp.br/handle/OPI/88369


